ABOUT US
SCIENCE
FACILITY
INVESTORS
Media
Notice
Public Disclosures
Stock Information
Financials
ESG
ESG Management
Archive
CONTACT
ABOUT US
SCIENCE
FACILITY
INVESTORS
Media
Notice
Public Disclosures
Stock Information
Financials
ESG
ESG Management
Archive
CONTACT
INVESTORS
[비즈트리뷴] “큐로셀, 국내 CAR-T치료제 대체하게 될 것” – 유진투자
2024/12/12
“큐로셀, 국내 CAR-T치료제 대체하게 될 것” – 유진투자 – 비즈트리뷴
Prev
큐로셀 CAR-T 치료제 ‘안발셀’, 허가-평가-협상 병행 2호 선정
Next
[더벨] 예상보다 늦어진 품목허가, 빠른 상업화 위한 전략적 지연
ABOUT US
SCIENCE
FACILITY
INVESTORS
Media
Notice
Public Disclosures
Stock Information
Financials
ESG
ESG Management
Archive
CONTACT
ABOUT US
SCIENCE
FACILITY
INVESTORS
Media
Notice
Public Disclosures
Stock Information
Financials
ESG
ESG Management
Archive
CONTACT
Copyright 2023. Curocell Inc. All Rights Reserved.